A study will be initiated in September, 2011 plans to look at whether regular exercise will increase production of a growth protein for the brain and reverse some of the damaging effects of fetal alcohol spectrum disorder, also known as FASD.

There is a great site called the Homelessness Resource Center which contains information about FASD.According to the site:

What is the Homelessness Resource Center?

We are an interactive community of providers, consumers, policymakers, researchers, and public agencies at federal, state, and local levels. We share state-of-the art knowledge and promising practices to prevent and end homelessness through:

•  Training and technical assistance.
•   Publications and materials.
•   On-line learning opportunities.
•   Networking and collaboration.

When you have an opportunity please visit the multiple resources on the Homelessness Resource Site.

Help spread the word by joining the federal government in an effort to ending childhood hunger. Please be so kind to distribute the attached flyer re: the “Summer Meals for Kids” program to your key community and faith-based
organizations regarding this initiative.

Summer Meals for Kids flyer

Summer Meals for Kids Spanish Flyer
Also,  there is a valuable website which provides online tools and volunteer initiatives around ending childhood hunger that you may include in what you are already doing. These online tools offer the opportunity for you and your staff to renew your commitment to the cause, to explore new ways to work toward this goal and to join the chorus of others doing the same in communities
across the country. Visit the End Hunger Website NOW.

WASHINGTON, D.C. – The U.S. Consumer Product Safety Commission, in cooperation
with the firm named below, today announced a voluntary recall of the following
consumer product. Consumers should stop using recalled products immediately
unless otherwise instructed. It is illegal to resell or attempt to resell
a recalled consumer product.

Name of Product: Mizuno Supreme Series and Ballpark Pro baseball and softball
gloves

Units: About 131,000

Importer: Mizuno USA Inc., of Norcross, Ga.

Hazard: Some gloves were found to contain a variety of molds that could
cause respiratory or other infections in individuals with chronic health
problems, or in individuals who have impaired immune systems.

Incidents/Injuries: None reported.

Description: The recalled items are leather Mizuno baseball and softball
gloves. The gloves have a sewn-in white label on the heel of the glove
with the words “Made in Vietnam” and the model number. Supreme
Series gloves affected are further identified by the date code imprinted
on the heel of the glove near the thumb opening. The following models are
affected by this recall:

Model | Description | Date Code

GSP1251TG | The glove is dark brown on the top and palm sides with a yellow
wrist strap. The words “SUPREME SERIES” are stamped into the
palm of the gloves. | SV0910, SV1110, SV1210, SV0111, SV0311

GSP1300T | The glove is light tan on the top and palm sides with a dark
brown wrist strap and dark brown bindings. The words “SUPREME SERIES”
are printed in dark brown on the palm of the gloves. | SV0310

GSP1401TG | The glove is dark tan on the top and palm sides with a brown
wrist strap and dark brown bindings. The words “SUPREME SERIES”
are printed in dark brown on the palm of the gloves. | SV0610, SV0910,
SV1010, SV1110, SV0111, SV0311

MMX122P | The glove is dark brown on the top and palm sides with a dark
brown wrist strap and dark brown bindings. The words “BALLPARK PRO”
are printed in gold on the palm of the gloves. | N/A

MMX115PWM | The glove is tan on the top and palm sides with a light tan
wrist strap and dark brown bindings. The words “BALLPARK PRO”
are printed in dark brown on the palm of the gloves. | N/A

MMX130 | The glove is tan on the top with dark brown palm and webbing and
tan wrist strap and bindings. The words “BALLPARK PRO” are printed
in gold on the palm of the gloves. | N/A

Sold at: Walmart and Target stores nationwide from April 2010 through May
2011 for between $24 and $60.

Manufactured in: Vietnam

Remedy: Consumers should immediately stop using the gloves and contact
Mizuno USA to receive a full refund.

Consumer Contact: For additional information, contact Mizuno USA Inc. at
(800) 451-7913 between 8:30 a.m. and 5:30 p.m. ET Monday through Friday.

Click here to see this recall on CPSC’s web site, including pictures of the recalled
products.

Tamiflu is in a class of medications called neuraminidase inhibitors. These

drugs work by stopping the spread of the influenza (flu) virus in the body.

Genentech, the manufacturer of Tamiflu for oral suspension, plans to begin

distribution of the new 6 mg/mL product in July 2011. The company has instituted

a voluntary Take Back Program for wholesale buyers, distributors and pharmacies

to remove the 12 mg/mL product from the marketplace. The 12 mg/mL product

will remain in the marketplace and in state or national stockpiles until

current supplies expire.

RECOMMENDATION: It is important

for healthcare professionals to be aware that a patient may potentially

receive either concentration (6 mg/mL or 12 mg/mL) from their pharmacy

during the next influenza season (2011-2012). Steps should be taken to

avoid the potential for a medication error due to confusion between the

two concentrations. Prescribers should include the new concentration (6

mg/mL) and dose in milliliters on all prescriptions for Tamiflu for oral

suspension.

Healthcare professionals and patients

are encouraged to report adverse events or side effects related to the

use of these products to the FDA’s MedWatch Safety Information and Adverse

Event Reporting Program:

* Complete and submit the report Online:

www.fda.gov/MedWatch/report.htm

* Download form or call 1-800-332-1088

to request a reporting form, then complete and return to the address on

the pre-addressed form, or submit by fax to 1-800-FDA-0178

Read the MedWatch safety alert, including a link to the Drug Safety Communication

A recently released guide from the Centers of Disease Control  details minimum expectations for safe care and  recommends every practice
identify an infection prevention leader.
Medical care in outpatient settings has surged in recent years, yet in many cases, adherence to standard infection prevention practices in outpatient settings is lacking.

To protect patients and help educate clinicians about minimum expectations of safe care, the Centers for Disease Control and Prevention today released a new, concise guide and checklist specifically for health care providers in outpatient care settings such as endoscopy clinics, surgery centers, primary care offices, and pain management clinics.

Read more about this guide and how to obtain it today!

The MedWatch June 2011 Safety Labeling Changes posting includes 50 products with safety labeling changes to the following
sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE
REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.

The “Summary Page” provides a listing of drug names and safety labeling sections revised:

Clicking on a drug product name in the Summary View will take you to the “detailed view” page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information.

The following drugs had modifications to
the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections:

Avalide (irbesartan/hydrochlorothiazide)
tablets

Avodart (dutasteride) soft gelatin
capsules

Corgard (nadolol) tablets

Corzide (nadolol and bendroflumethiazide)
tablets

Diflucan (fluconazole) tablets,
I.V, and oral suspension

Diovan (valsartan) tablets

Ditropan XL (oxybutynin chloride)
tablets

Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)
tablets

Feraheme (ferumoxytol) injection

Fioricet with Codeine (butalbital,
acetaminophen, caffeine, and codeine phosphate) Capsules

Jalyn (dutasteride and tamsulosin)
capsules

Kenalog-10 (triamcinolone acetonide)
injection and Kenalog-40 (triamcinolone acetonide) injection

Nexium (esomeprazole magnesium)
for delayed-release oral suspension, delayed-release capsules and (esomeprazole
sodium) for injection

Photofrin (porfimer sodium) for
injection

Prilosec (omeprazole magnesium)
for delayed-release oral suspension and delayed-release capsules

Proscar (finasteride) tablets

Prozac Pulvules (fluoxetine hydrochloride)
capsules for oral use and Prozac Weekly (fluoxetine hydrochloride) delayed-release
capsules

Renagel (sevelamer hydrochloride)
tablets and Renvela (sevelamer carbonate) powder for oral suspension and
tablets

Simcor (niacin extended-release/simvastatin)
tablets

Sumavel DosePro (sumatriptan) injection
for subcutaneous use

Talacen (pentazocine hydrochloride
and acetaminophen) tablets

Tekturna HCT (aliskiren/hydrochlorothiazide)
tablets

Torisel (temsirolimus) injection

Ultracet (tramadol HCl/acetaminophen)
tablets

Venofer (iron sucrose) injection

Vimovo (naproxen/esomeprazole magnesium)
tablets

Vytorin (ezetimibe/simvastatin)
tablets

Zmax (azithromycin extended release)
for oral suspension

Zocor (simvastatin) tablets